UroGen Pharma (URGN) Tops Q3 EPS by 3c

UroGen Pharma (NASDAQ: URGN) reported Q3 EPS of ($1.13), $0.03 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $16.01 million versus the consensus estimate of $20.15 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c